SEC EDGAR · Company announcement
COR: Financial results · Company disclosure
Filed 8-K for an event or period dated 2026-10-21. Financial results; Company disclosure.
Follow COR- Became public
- Oct 21, 2026, 7:48 AM EDT
- Event / period date
- Oct 21, 2026
- Collected
- Nov 7, 2026, 10:16 PM EST
Why this is connected
This filing identifies Cencora, Inc. as the issuer of the security. The company's SEC identifier connects it to COR.
Joint Press Release dated October 21, 2026 of Cencora, Inc. and American Oncology Network, Inc. ↗Source evidence
Read the source excerpt or record
Item 2.02 Results of Operations and Financial Condition. On October 21, 2026, Cencora, Inc., a Delaware corporation (the “Company”), announced updated fiscal year 2026 financial expectations and the transaction described in Item 7.01 below, pursuant to the news release described in Item 7.01 below. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The updated financial expectations included in the news release described in Item 7.01 below are based on information available to Company management as of the date of the news release. In addition, because the Company’s financial closing procedures for the full-year 2026 are not yet complete, the Company’s actual results may change as a result of such financial closing procedures, final adjustments, management’s review of results, and other developments that may arise between the date of the news release and the time financial results for the full-year 2026 are finalized. The Company will discuss its expectations for fiscal 2027 on its fiscal fourth quarter 2026 earnings call on November 4, 2026. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under this Item 2.02 and Item 7.01 below, is being furnished to the Securities and Exchange Commission (the “SEC”) and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 7.01 Regulation FD
Congressional trading in COR
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026
- Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026 · Dependent
- Apr 30, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded Mar 31, 2026 · disclosed Apr 30, 2026
- Apr 30, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded Mar 23, 2026 · disclosed Apr 30, 2026
- Apr 30, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded Mar 23, 2026 · disclosed Apr 30, 2026 · Dependent
- Jun 22, 2025$50K–$100K
Rep. Jefferson Shreve (R-IN-6)
$50K–$100K · Traded May 12, 2025 · disclosed Jun 22, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.